• 1
    Posner M, Hershok DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007; 357: 17051715.
  • 2
    Vermorken JB, Remenar E, Van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007; 357: 16951704.
  • 3
    Posner M, Vermorken JB. Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer. Semin Oncol. 2008; 35: 221228.
  • 4
    Fury MG, Shah JP. Induction chemotherapy in the management of head and neck cancer. J Surg Oncol. 2010; 101: 292298.
  • 5
    Figlin RA, Brown E, Armstrong AJ, et al. NCCN task force report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw. 2008; 6( suppl 5): S1S22.
  • 6
    Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007; 12: 922.
  • 7
    Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006; 22: 159168.
  • 8
    Molinolo AA, Hewitt SM, Amornphimoltham P, et al. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the Head and Neck Cancer Tissue Array Initiative. Clin Cancer Res. 2007; 13: 49644973.
  • 9
    Morris LG, Taylor BS, Bivona TG, et al. Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc Natl Acad Sci U S A. 2011; 108: 1902419029.
  • 10
    Aissat N, Le Tourneau C, Ghoul A, et al. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol. 2008; 62: 305313.
  • 11
    Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills GB. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res. 1995; 55: 19821988.
  • 12
    Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damage induced apoptosis though inhibition of p21 translation. Cell. 2005; 120: 747759.
  • 13
    Mondesire WH, Jian W, Zhang H, et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res. 2004; 10: 70317042.
  • 14
    Chu W, Wangpaichitr M, Feun L, et al. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer [serial online]. Mol Cancer. 2005; 4: 25.
  • 15
    Fury MG, Sherman E, Haque S, et al. A phase I study of everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012; 69: 591598.
  • 16
    Ross RW, Manola J, Oh WK, et al. Phase I trial of RAD001 and docetaxel in castration resistant prostate cancer with FDG-PET assessment of RAD001 activity [abstract]. J Clin Oncol. 2008; 26( May 20 suppl). Abstract 5069.
  • 17
    Punt CJA, Boni J, Bruntsch U, Peters M, Thielert C. Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol. 2003; 14: 931937.
  • 18
    Posner MR, Glisson B, Frenette G, et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2001; 19: 10961104.
  • 19
    Schrijvers D, Van Herpen C, Kerger J, et al. Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. Ann Oncol. 2004; 15: 638645.
  • 20
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205216.
  • 21
    Guo M, Gong Y, Deavers M, et al. Evaluation of commercialized in situ hybridization assay for detecting human papillomavirus DNA in tissue specimens from patients with cervical intraepithelial neoplasia and cervical carcinoma. J Clin Microbiol. 2008; 46: 274280.
  • 22
    Vakiani E, Janakiraman M, Shen R, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol. 2012; 30: 29562962.
  • 23
    Janakiraman M, Vakiani E, Zeng Z, et al. Genomic and biologic characterization of exon 4 KRAS mutations in human cancer. Cancer Res. 2010; 70: 59015911.
  • 24
    Reidy DL, Vakiani E, Fakih MG, et al. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol. 2010; 28: 42404246.
  • 25
    O'Donnell A, Faivre S, Burris HA, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol. 2008; 26: 15881595.
  • 26
    McLellan RA, Drobitch RK, Monshouwer M, Renton KW. Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab Dispos. 1996; 24: 11341138.
  • 27
    Kletzl H, Zwanziger E, Kirkpatrick C, Luedin E. Effect of ciprofloxacin on the systemic exposure to erlotinib [abstract]. J Clin Oncol. 2008; 26( suppl). Abstract 19047.
  • 28
    Andre F, Campone M, O'Regan R, et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol. 2010; 28: 51105115.
  • 29
    Campone M, Levy V, Bourbouloux E, et al. Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumors. Br J Cancer. 2009; 100: 315321.
  • 30
    Kollmannsberger C, Hirte H, Siu LL, et al. Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase 1, open-label dose-escalation study (IND 179). Ann Oncol. 2012; 23: 238244.
  • 31
    Moulder S, Gladish G, Ensor J, et al. A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer. 2012; 118: 23782384.
  • 32
    Ramalingam SS, Harvey D, Saba N, et al. Phase I and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel in recurrent/refractory nonsmall cell lung cancer. Cancer. 2010; 116: 39033909.
  • 33
    Fury MG, Sherman E, Ho A, et al. A phase I study of temsirolimus + carboplatin + paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). Cancer Chemother Pharmacol. 2012; 70: 121128.
  • 34
    Fury MG, Drobnjak M, Sima C, et al. Tissue microarray analysis demonstrates association between p16 and phosphorylated eIF4E in tonsillar squamous cell carcinoma. Head Neck. 2011; 22: 13401345.
  • 35
    Molinolo AA, Marsh C, El Dinali M, et al. mTOR as a molecular target of HPV-associated oral and cervical squamous carcinomas. Clin Cancer Res. 2012; 18: 25582568.
  • 36
    Won HS, Jung C-W, Chun SH, et al. Difference in expression of EGFR, pAKT, and PTEN between oropharyngeal and oral cavity squamous cell carcinoma. Oral Oncol. 2012; 48: 985990.
  • 37
    Spangle JM, Munger K. The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis. J Virol. 2010; 84: 93989407.
  • 38
    Spangle JM, Ghosh-Choudhury N, Munger K. Activation of cap-dependent translation by mucosal human papillomavirus E6 proteins in dependent on the integrity of the LXXLL binding motif. J Virol. 2012; 86: 74667472.
  • 39
    Fury MG, Sherman EJ, Ho AL, et al. A phase I study of everolimus (E) plus weekly cisplatin (CDDP) plus intensity-modulated radiation therapy (IMRT) in head and neck (HN) cancer [abstract]. J Clin Oncol. 2012; 30( suppl). Abstract 5545.